Browsing Tag
Ligand Pharmaceuticals
6 posts
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.
What John M. Gay’s CFO appointment means for Pelthos Therapeutics (NYSE American: PTHS) and its next growth phase
Pelthos Therapeutics has named John M. Gay as CFO. Read what the move signals for Zelsuvmi growth, funding strategy, and Pelthos stock now.
Ovid Therapeutics (NASDAQ: OVID) surges 28% on $175m private placement: What does it mean for biotech investors?
Ovid Therapeutics (NASDAQ: OVID) jumped 28% after securing $175M via a PIPE deal. Explore its pipeline focus, stock sentiment, and investor outlook.
Primrose Bio emerges as biotech powerhouse, secures $15m from Ligand Pharmaceuticals
Primrose Bio, Inc. has been founded as a merger between Primordial Genetics, Inc. and Pelican Technology Holdings, Inc…
Ligand Pharmaceuticals to acquire protein therapeutics developer Pfenex
US biopharma company Ligand Pharmaceuticals has signed a deal worth up to $516 million to acquire Pfenex, a…